These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 34867818)

  • 41. Multi-omics in high-grade serous ovarian cancer: Biomarkers from genome to the immunome.
    Clifford C; Vitkin N; Nersesian S; Reid-Schachter G; Francis JA; Koti M
    Am J Reprod Immunol; 2018 Aug; 80(2):e12975. PubMed ID: 29781548
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Lynch syndrome-associated epithelial ovarian cancer and its immunological profile.
    Rasmussen M; Lim K; Rambech E; Andersen MH; Svane IM; Andersen O; Jensen LH; Nilbert M; Therkildsen C
    Gynecol Oncol; 2021 Sep; 162(3):686-693. PubMed ID: 34275654
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Metabolic reprogramming due to hypoxia in pancreatic cancer: Implications for tumor formation, immunity, and more.
    Hao X; Ren Y; Feng M; Wang Q; Wang Y
    Biomed Pharmacother; 2021 Sep; 141():111798. PubMed ID: 34120068
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Fertility preservation in ovarian cancer patients.
    Santos ML; Pais AS; Almeida Santos T
    Gynecol Endocrinol; 2021 Jun; 37(6):483-489. PubMed ID: 33501866
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Significance of CD47 and Its Association With Tumor Immune Microenvironment Heterogeneity in Ovarian Cancer.
    Yu L; Ding Y; Wan T; Deng T; Huang H; Liu J
    Front Immunol; 2021; 12():768115. PubMed ID: 34966389
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Epithelial ovarian cancer and fertility preservation: Article drafted from the French Guidelines in oncology entitled "Initial management of patients with epithelial ovarian cancer" developed by FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY under the aegis of CNGOF and endorsed by INCa].
    Uzan C; Courbiere B; Chabbert-Buffet N
    Gynecol Obstet Fertil Senol; 2019 Feb; 47(2):180-186. PubMed ID: 30704956
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Treatment for recurrent epithelial ovarian cancer.
    Li YT; Liu CH; Wang PH
    Taiwan J Obstet Gynecol; 2021 Sep; 60(5):803-804. PubMed ID: 34507651
    [No Abstract]   [Full Text] [Related]  

  • 48. Therapeutic effect of dual CAR-T targeting PDL1 and MUC16 antigens on ovarian cancer cells in mice.
    Li T; Wang J
    BMC Cancer; 2020 Jul; 20(1):678. PubMed ID: 32689954
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Strengthening the AntiTumor NK Cell Function for the Treatment of Ovarian Cancer.
    Greppi M; Tabellini G; Patrizi O; Candiani S; Decensi A; Parolini S; Sivori S; Pesce S; Paleari L; Marcenaro E
    Int J Mol Sci; 2019 Feb; 20(4):. PubMed ID: 30791364
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Opportunities in immunotherapy of ovarian cancer.
    Coukos G; Tanyi J; Kandalaft LE
    Ann Oncol; 2016 Apr; 27 Suppl 1(Suppl 1):i11-i15. PubMed ID: 27141063
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Tumor-associated macrophage-targeted therapeutics in ovarian cancer.
    An Y; Yang Q
    Int J Cancer; 2021 Jul; 149(1):21-30. PubMed ID: 33231290
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Borderline Ovarian Tumours: CNGOF Guidelines for Clinical Practice - Diagnosis and Management of Recurrent Borderline Ovarian Tumours].
    Gauroy E; Larouzée E; Chéreau E; De La Motte Rouge T; Margueritte F; Sallée C; Lacorre A; Gauthier T; Koskas M
    Gynecol Obstet Fertil Senol; 2020 Mar; 48(3):314-321. PubMed ID: 32004781
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The tubal epigenome - An emerging target for ovarian cancer.
    Reavis HD; Drapkin R
    Pharmacol Ther; 2020 Jun; 210():107524. PubMed ID: 32197795
    [TBL] [Abstract][Full Text] [Related]  

  • 54. CXC Chemokine Signaling in Progression of Epithelial Ovarian Cancer: Theranostic Perspectives.
    Huang X; Hao J; Tan YQ; Zhu T; Pandey V; Lobie PE
    Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269786
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Emerging immunotherapies in ovarian cancer.
    Ojalvo LS; Nichols PE; Jelovac D; Emens LA
    Discov Med; 2015 Sep; 20(109):97-109. PubMed ID: 26463091
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Macrophages derived exosomes deliver miR-223 to epithelial ovarian cancer cells to elicit a chemoresistant phenotype.
    Zhu X; Shen H; Yin X; Yang M; Wei H; Chen Q; Feng F; Liu Y; Xu W; Li Y
    J Exp Clin Cancer Res; 2019 Feb; 38(1):81. PubMed ID: 30770776
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Immunotherapy and the ovarian cancer microenvironment: Exploring potential strategies for enhanced treatment efficacy.
    Wang ZB; Zhang X; Fang C; Liu XT; Liao QJ; Wu N; Wang J
    Immunology; 2024 Sep; 173(1):14-32. PubMed ID: 38618976
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Metabolic factors contribute to T-cell inhibition in the ovarian cancer ascites.
    Gong Y; Yang J; Wang Y; Xue L; Wang J
    Int J Cancer; 2020 Oct; 147(7):1768-1777. PubMed ID: 32208517
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comprehensive of N1-Methyladenosine Modifications Patterns and Immunological Characteristics in Ovarian Cancer.
    Liu J; Chen C; Wang Y; Qian C; Wei J; Xing Y; Bai J
    Front Immunol; 2021; 12():746647. PubMed ID: 34777359
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Low-grade epithelial ovarian cancer: what a radiologist should know.
    Elsherif S; Javadi S; Viswanathan C; Faria S; Bhosale P
    Br J Radiol; 2019 Mar; 92(1095):20180571. PubMed ID: 30604635
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.